Phase IA/II, multicentre, open‐label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐Hodgkin or Hodgkin lymphoma

Summary Despite advancements in the treatment of non‐Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), patients continue to relapse and thus a need for new targeted therapies remains. The CD40 receptor is highly expressed on neoplastic B cells and activation leads to enhanced proliferation and survi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2014-01, Vol.164 (2), p.258-265
Hauptverfasser:	Fanale, Michelle, Assouline, Sarit, Kuruvilla, John, Solal‐Céligny, Philippe, Heo, Dae S., Verhoef, Gregor, Corradini, Paolo, Abramson, Jeremy S., Offner, Fritz, Engert, Andreas, Dyer, Martin J. S., Carreon, Daniel, Ewald, Brett, Baeck, Johan, Younes, Anas, Freedman, Arnold S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Biological and medical sciences CD40 Antigens - antagonists & inhibitors Female Hematologic and hematopoietic diseases Hodgkin Disease - drug therapy Hodgkin Disease - pathology Hodgkin lymphoma Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - pathology Male Medical sciences Middle Aged monoclonal antibodies Neoplasm Staging non‐Hodgkin lymphoma Treatment Outcome Tumors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!